Review Article
Advances in Molecular Imaging Strategies for In Vivo Tracking of Immune Cells
Table 1
Immune cell tracking imaging strategies.
| Types of cells | Labeling strategy | Imaging modality | Labeling method | Subject | Duration of tracking | Purpose | Clinical translation | Reference |
| DC | Direct | FLI | NIR-QD | Mouse | 3 days | Tracking study | Limited | [4] | PET | 18F-SFB | Mouse | 4 h | Tracking study | Yes | [44] | SPECT | 111Indium | Human | 24–48 h | Tracking study | Yes | [43] | SPECT | 111Indium/Tc-HMPAO | Human | 48–72 h | Tracking study | Yes | [48] |
| DC | Indirect | BLI | Fluc | Mouse | 4 days | Tracking study | Limited | [47] | PET | NIS/124I | Mouse | 4 days | Tracking study | Yes | [47] | MRI | FTH | Mouse | 48 h | Tracking study | Yes | [45] |
| Macrophage | Direct | FLI | NIR nanoparticle | Mouse | 3–24 h | Tracking to inflammation | Limited | [20] | MRI | SPIO | Mouse | 24 h | Tracking to inflammation | Yes | [49] | MRI | Magnetic nanoparticle | Mouse | 3–24 h | Tracking to inflammation | Yes | [20] | MRI | SPIO | Mouse | 6–13 days | Tracking to rheumatoid arthritis | Yes | [50] |
| Macrophage | Indirect | BLI | Fluc | Mouse | 0–21 days | Tracking to inflammation | Limited | [51] | BLI | Fluc | Mouse | 1–4 days | Colon tumor targeting | Limited | [52] | PET | NIS/124I | Mouse | 7 days | Tracking to inflammation | Yes | [53] | PET | NIS/124I | Mouse | 8–21 days | Tracking to inflammation | Yes | [51] | PET/CT | 18F-FB | Mouse | 3 h | Tracking to lung carcinoma | Yes | [54] |
| T cells | Direct | MRI | IOPC-NH2 | Rat | 24–48 h | Tracking study | Yes | [49] | MRI | PFPE/19F | Mouse | 48 h | Tracking study | Yes | [55] |
| T cells | Indirect | BLI | Fluc | Mouse | 24 h | Tracking study | Limited | [56] | BLI | Fluc | Mouse | 10 days | Tracking to lung carcinoma | Limited | [57] | PET/CT | sr39tk/18F-FHBG | Mouse | 1–21 days | Melanoma tumor targeting | Yes | [58] |
| B cells | Direct | FLI | NIR nanoparticle | Mouse | 1–15 days | Tracking study | Limited | [59] | PET/CT | 89Zr-anti-B220 | Mouse | 15–72 h | Biodistribution study | Yes | [60] |
| B cells | Indirect | MRI | SPIO | Mouse | 1–15 days | Tracking study | Yes | [60] |
| NK | Direct | FLI | NIR dye | Rat | 24 h | Tracking study | Limited | [61] | PET | 11C | Mouse | 0.5–1 h | Tracking study | Yes | [62] | SPECT | 111In | Human | 0.5–144 h | Tracking and therapy study | Yes | [63] | SPECT | 111In | Human | 6 days | Biodistribution study | Yes | [64] | SPECT | 111In | Human | 6–96 h | Tracking study | Yes | [63] |
|
|
DC: dendritic cell, NK: natural killer cell, FLI: fluorescence imaging, PET: positron emission tomography, SPECT: single photon emission computerized tomography, BLI: bioluminescence imaging, MRI: magnetic resonance imaging, CT: computed tomography, NIR: near infrared, QD: quantum dot, SFB: fluorobenzoate, NIS: sodium iodide symporter, HMPAO: hexamethylpropyleneamineoxime, SPIO: superparamagnetic iron oxide, Fluc: firefly luciferase, FB: fluorobenzene, IOPC: iron oxide nanoparticles coated, PFPE: perfluoropolyethers, sr39tk: mutant type of HSV-thymidine kinase, and FHBG: fluorohydroxymethyl butyl guanine.
|